SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).

被引：9
|
作者：
Lowe, Elizabeth S.
Jayawardene, Deepthi
Penson, Richard T.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5598
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial
    Classe, Jean-Marc
    Meeus, Pierre
    Leblanc, Eric
    Wernert, Romuald
    Quenet, Francois
    Marchal, Frederic
    Houvenaeghel, Gilles
    Bats, Anne-Sophie
    Ferron, Gwenael
    Brigand, Cecile
    Berton, Dominique
    Gladieff, Laurence
    Joly, Florence
    Ray-Coquard, Isabelle Laure
    Durand-Fontanier, Sylvaine
    Liberale, Gabriel
    Brument, Emilie
    Asselain, Bernard
    Campion, Loic
    Glehen, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
    Matulonis, U. A.
    Penson, R. T.
    Domchek, S. M.
    Kaufman, B.
    Shapira-Frommer, R.
    Audeh, M. W.
    Kaye, S.
    Molife, L. R.
    Gelmon, K. A.
    Robertson, J. D.
    Mann, H.
    Ho, T. W.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1013 - 1019
  • [43] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Reni, Michele
    Kindler, Hedy L.
    Hammel, Pascal
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golani, Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Algul, H.
    Reni, M.
    Kindler, H. L.
    Hammel, P.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y
    Reinacher-Schick, A.
    Tortora, G.
    O'Reilly, E.
    McGuiness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Golan, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 216 - 216
  • [45] REAL WORLD OUTCOMES OF OLAPARIB MAINTENANCE THERAPY IN PATIENTS WITH BRCA1/2-MUTATED PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER
    McLaren, A.
    White, M.
    Cartwright, D.
    Brown, J.
    Randhawa, M.
    Roxburgh, T.
    Glasspool, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A166 - A166
  • [46] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 18, pg 1274, 2017)
    Pujade-Lauraine, E.
    Ledermann, J. A.
    Selle, F.
    LANCET ONCOLOGY, 2017, 18 (09): : E510 - E510
  • [47] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Moore, K. N.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    DiSilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 727 - 727
  • [48] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Friedlander, M.
    Moore, K.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    Disilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
    Li, Ning
    Bu, Hualei
    Liu, Jihong
    Zhu, Jianqing
    Zhou, Qi
    Wang, Li
    Yin, Rutie
    Wu, Xiaohua
    Yao, Shuzhong
    Gu, Kangsheng
    Zhang, Hui
    Li, Guiling
    Pan, Hongming
    Wu, Qiang
    An, Ruifang
    Yang, Xinfeng
    Zhu, Yaping
    Wan, Xiaoping
    Duan, Wei
    Xiong, Jianping
    Guo, Hongyan
    Lou, Ge
    Wang, Jing
    Hu, Wenjing
    Zhang, Xin
    Meng, Yuanguang
    Zhang, Ben
    Wang, Yuting
    Wang, Quanren
    Wu, Lingying
    CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2452 - 2458
  • [50] Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
    Liu, Ying L.
    Mathews, Cara A.
    Simpkins, Fiona
    Cadoo, Karen A.
    Provencher, Diane
    Mccormick, Colleen C.
    Elnaggar, Adam C.
    Altman, Alon D.
    Gilbert, Lucy
    Black, Destin
    Kabil, Nashwa
    Taylor, Rosie N.
    Barnicle, Alan
    Munley, Jiefen Y.
    Aghajanian, Carol
    CANCER, 2025, 131 (02)
12345